Elezanumab

View Clinical trials for Elezanumab Get Elezanumab Patent Info for Free

ABT-555 is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and multiple sclerosis.

Inn NameElezanumab
Lab CodesABT-555, AE12-1Y-QL (derived from parental mAb AE12-1 and AE12-1Y)
Chemical NameImmunoglobulin G1-lambda1, anti-[Homo sapiens RGMA (repulsive guidance molecule family member a, repulsive guidance molecule A, RGMa)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-450) [Homo sapiens VH (IGHV1- 18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13](1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), hinge (219-233), CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448),CHS (449-450)) (121-450)], (223- 214')-disulfide with lambda1 light chain (1'-215') [Homo sapiens V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimer (229-229'':232-232'')-bisdisulfide
Alternate NameImmunoglobulin G1-lambda1, anti-(homo sapiens rgma (repulsive guidance molecule family member A, repulsive guidance molecule A, rgma)), homo sapiens monoclonal antibody;
Immunoglobulin, anti-(repulsive guidance molecule rgma) (human monoclonal PR-1432051 heavy chain), disulfide with human monoclonal PR-1432051 light chain, dimer
SequenceHeavy chain
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SHGISWVRQA PGQGLDWMGW 50
ISPYSGNTNY AQKLQGRVTM TTDTSTSTAY MELSSLRSED TAVYYCARVG 100
SGPYYYMDVW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP 250
KDQLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHNHYT QKSLSLSPGK 450

Light chain
QSALTQPRSV SGSPGQSVTI SCTGTSSSVG DSIYVSWYQQ HPGKAPKLML 50
YDVTKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC YSYAGTDTLF 100
GGGTKVTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS 215

Disulfide bridges location
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22''-96'' 147''-203'' 264''-324'' 370''-428''
Intra-L (C23-C104) 22'-90' 137'-196'
22'''-90''' 137'''-196'''
Inter-H-L (h 5-CL 126) 223-214' 223''-214'''
Inter-H-H (h 11, h 14) 229-229' 232-232''
N-glycosylation sites
H CH2 N84.4:
300, 300''
Fucosylated complex bi-antennary CHO-type glycans
Chemical StructureElezanumab.png
Cas Registry Number1791416-49-3
New Molecular EntityYes
OriginatorAbbVie
Mechanism Of ActionRGMa inhibitor
Who Atc CodesN07X (Other Nervous System Drugs)
Ephmra CodesN7 (Other CNS Drugs)
IndicationMultiple Sclerosis

Free counters!